Viral nanoparticles: Current advances in design and development

Arul, Sanjivi; Balakrishnan, Brinda; Handanahal, Savithri S; Venkataraman, Sangita

doi:10.1016/j.biochi.2023.08.006

Cited by 9 publications

(8 citation statements)

References 177 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Viral nanoparticles (VNPs) or non-infectious virus-like particles (VLPs) are being explored as self-assembling, efficient, and adaptable drug delivery systems used in various applications [ 12 , 13 ]. VNPs are nanomaterials that are derived from viruses (human, bacterial, plant).…”

Section: Viral Nanoparticlesmentioning

confidence: 99%

See 1 more Smart Citation

Precise Therapy Using the Selective Endogenous Encapsidation for Cellular Delivery Vector System

Tatarūnas,

Čiapienė,

Giedraitienė

2024

Pharmaceutics

View full text Add to dashboard Cite

Interindividual variability in drug response is a major problem in the prescription of pharmacological treatments. The therapeutic effect of drugs can be influenced by human genes. Pharmacogenomic guidelines for individualization of treatment have been validated and used for conventional dosage forms. However, drugs can often target non-specific areas and produce both desired and undesired pharmacological effects. The use of nanoparticles, liposomes, or other available forms for drug formulation could help to overcome the latter problem. Virus-like particles based on retroviruses could be a potential envelope for safe and efficient drug formulations. Human endogenous retroviruses would make it possible to overcome the host immune response and deliver drugs to the desired target. PEG10 is a promising candidate that can bind to mRNA because it is secreted like an enveloped virus-like extracellular vesicle. PEG10 is a retrotransposon-derived gene that has been domesticated. Therefore, formulations with PEG10 may have a lower immunogenicity. The use of existing knowledge can lead to the development of suitable drug formulations for the precise treatment of individual diseases.

show abstract

Section: Viral Nanoparticlesmentioning

confidence: 99%

“…However, host immunogenicity may remain an obstacle to the clinical use of certain VNPs. Recognition of viral components can trigger an immune response that leads to clearance of them from the organism [ 13 ].…”

Section: Viral Nanoparticlesmentioning

confidence: 99%

Precise Therapy Using the Selective Endogenous Encapsidation for Cellular Delivery Vector System

Tatarūnas,

Čiapienė,

Giedraitienė

2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Technology-oriented research and developments include uses of viral nanoparticles (VNPs) and virus-like particles (VLPs) as biotemplates for inorganic and organic compounds, and uses as carriers for biomolecules [11]. Thirty years of creative developments have given rise to an enormous variety of novel colloidal (particulate), layered and volume materials, either active by themselves as hybrid structures, or after an integration into technical devices [110][111][112][113][114][115][116][117][118][119][120][121]. The following showcases only a small selection out of the many exciting overviews and cuttingedge studies.…”

Section: |3|3 Novel Applications: Increasing Demand: Tobamovirus Part...mentioning

confidence: 99%

Getting Hold of the Tobamovirus Particle – Why and How? Purification Routes over Time and a New Customizable Approach

Wendlandt,

Britz,

Kleinow

et al. 2024

Preprint

View full text Add to dashboard Cite

This article develops a multi-perspective view on motivations and methods for tobamovirus purification through the ages, and presents a novel efficient, easy-to-use approach that can be well-adapted to different species of native and functionalized virions. We survey the various driving forces prompting researchers to enrich tobamoviruses: from the search for the causative agents of mosaic diseases in plants to their increasing recognition as versatile nanocarriers in biomedical and engineering applications. Best practice and also rarely applied options for the serial processing steps required for successful isolation of tobamoviruses are then reviewed. Adaptations for distinct particle species, pitfalls and 'forgotten' or underrepresented technologies are considered as well. The article is topped off with our own development of a method for virion preparation, rooted in historical protocols. It combines selective re-solubilization of polyethylene glycol (PEG) virion raw precipitates with density step gradient centrifugation in biocompatible iodixanol formulations, yielding ready-to-use particle suspensions. This newly established protocol and some considerations for perhaps worthwile further developments could serve as putative stepping stones towards preparation procedures appropriate for routine practical uses of the multivalent soft-matter nanorods.

show abstract

“…Nanoparticles or microspheres are new vaccine delivery systems [ 136 ]. Furthermore, nanoparticles or microspheres can protect the entrapped or attached viral antigens from proteases-mediated degradation at mucosal surfaces and induce robust mucosal immune response [ 137 , 138 , 139 ]. Li et al generated a nanoparticle-entrapped PEDV inactivated vaccine (strain AH2012/12) by using biodegradable poly (D,L-lactide-co-glycolide) and evaluated the immune responses in late-term pregnant sows and offspring piglets [ 140 ].…”

Section: Sec Vaccine Development In Chinamentioning

confidence: 99%

Prevention and Control of Swine Enteric Coronaviruses in China: A Review of Vaccine Development and Application

Kong,

Jia,

Xiao

et al. 2023

Vaccines

View full text Add to dashboard Cite

Swine enteric coronaviruses (SECs) cause significant economic losses to the pig industry in China. Although many commercialized vaccines against transmissible gastroenteritis virus (TGEV) and porcine epidemic diarrhea virus (PEDV) are available, viruses are still widespread. The recent emergence of porcine deltacoronavirus (PDCoV) and swine acute diarrhea syndrome coronavirus (SADS-CoV), for which no vaccines are available, increases the disease burden. In this review, we first introduced the genomic organization and epidemiology of SECs in China. Then, we discussed the current vaccine development and application in China, aiming to provide suggestions for better prevention and control of SECs in China and other countries.

show abstract

Viral nanoparticles: Current advances in design and development

Cited by 9 publications

References 177 publications

Precise Therapy Using the Selective Endogenous Encapsidation for Cellular Delivery Vector System

Precise Therapy Using the Selective Endogenous Encapsidation for Cellular Delivery Vector System

Getting Hold of the Tobamovirus Particle – Why and How? Purification Routes over Time and a New Customizable Approach

Prevention and Control of Swine Enteric Coronaviruses in China: A Review of Vaccine Development and Application

Contact Info

Product

Resources

About